These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 22579006)

  • 1. Preclinical pharmacokinetics of MI-219, a novel human double minute 2 (HDM2) inhibitor and prediction of human pharmacokinetics.
    Zou P; Zheng N; Yu Y; Yu S; Sun W; McEachem D; Yang Y; Yu LX; Wang S; Sun D
    J Pharm Pharm Sci; 2012; 15(2):265-80. PubMed ID: 22579006
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Interspecies scaling of interferon disposition and comparison of allometric scaling with concentration-time transformations.
    Lave T; Levet-Trafit B; Schmitt-Hoffmann AH; Morgenroth B; Richter W; Chou RC
    J Pharm Sci; 1995 Nov; 84(11):1285-90. PubMed ID: 8587044
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Applicability of the Øie-Tozer model to predict three types of distribution volume (Vd) in humans: Vd in central compartment, Vd at steady state, and Vd at beta phase.
    Yahata M; Ishii Y; Nakagawa T; Watanabe T; Miyawaki I
    Biopharm Drug Dispos; 2020 Apr; 41(4-5):151-165. PubMed ID: 32187715
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Development of a Physiologically Based Pharmacokinetic Model for Sinogliatin, a First-in-Class Glucokinase Activator, by Integrating Allometric Scaling, In Vitro to In Vivo Exploration and Steady-State Concentration-Mean Residence Time Methods: Mechanistic Understanding of its Pharmacokinetics.
    Song L; Zhang Y; Jiang J; Ren S; Chen L; Liu D; Chen X; Hu P
    Clin Pharmacokinet; 2018 Oct; 57(10):1307-1323. PubMed ID: 29626326
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prediction of the pharmacokinetic parameters of reduced-dolasetron in man using in vitro-in vivo and interspecies allometric scaling.
    Sanwald-Ducray P; Dow J
    Xenobiotica; 1997 Feb; 27(2):189-201. PubMed ID: 9058532
    [TBL] [Abstract][Full Text] [Related]  

  • 6. PhRMA CPCDC initiative on predictive models of human pharmacokinetics, part 3: comparative assessement of prediction methods of human clearance.
    Ring BJ; Chien JY; Adkison KK; Jones HM; Rowland M; Jones RD; Yates JW; Ku MS; Gibson CR; He H; Vuppugalla R; Marathe P; Fischer V; Dutta S; Sinha VK; Björnsson T; Lavé T; Poulin P
    J Pharm Sci; 2011 Oct; 100(10):4090-110. PubMed ID: 21541938
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Preclinical pharmacokinetics and in vitro metabolism of dasatinib (BMS-354825): a potent oral multi-targeted kinase inhibitor against SRC and BCR-ABL.
    Kamath AV; Wang J; Lee FY; Marathe PH
    Cancer Chemother Pharmacol; 2008 Mar; 61(3):365-76. PubMed ID: 17429625
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Characterization of preclinical in vitro and in vivo pharmacokinetics properties for KBP-7018, a new tyrosine kinase inhibitor candidate for treatment of idiopathic pulmonary fibrosis.
    Huang Z; Li H; Zhang Q; Tan X; Lu F; Liu H; Li S
    Drug Des Devel Ther; 2015; 9():4319-28. PubMed ID: 26273193
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mechanistic investigation of the preclinical pharmacokinetics and interspecies scaling of PF-05231023, a fibroblast growth factor 21-antibody protein conjugate.
    Giragossian C; Vage C; Li J; Pelletier K; Piché-Nicholas N; Rajadhyaksha M; Liras J; Logan A; Calle RA; Weng Y
    Drug Metab Dispos; 2015 Jun; 43(6):803-11. PubMed ID: 25805881
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Quantitative prediction of human pharmacokinetics and pharmacodynamics of imigliptin, a novel DPP-4 inhibitor, using allometric scaling, IVIVE and PK/PD modeling methods.
    Liu D; Ma X; Liu Y; Zhou H; Shi C; Wu F; Jiang J; Hu P
    Eur J Pharm Sci; 2016 Jun; 89():73-82. PubMed ID: 27108678
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Interspecies scaling: predicting volumes, mean residence time and elimination half-life. Some suggestions.
    Mahmood I
    J Pharm Pharmacol; 1998 May; 50(5):493-9. PubMed ID: 9643442
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Towards a better prediction of peak concentration, volume of distribution and half-life after oral drug administration in man, using allometry.
    Sinha VK; Vaarties K; De Buck SS; Fenu LA; Nijsen M; Gilissen RA; Sanderson W; Van Uytsel K; Hoeben E; Van Peer A; Mackie CE; Smit JW
    Clin Pharmacokinet; 2011 May; 50(5):307-18. PubMed ID: 21456631
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Nonclinical Pharmacokinetics and Prediction of Human Pharmacokinetics of SPH3127, a Novel Direct Renin Inhibitor.
    Zhang L; Mao Y; Gao Z; Chen X; Li X; Liu Y; Xia G
    Eur J Drug Metab Pharmacokinet; 2020 Feb; 45(1):15-26. PubMed ID: 31494843
    [TBL] [Abstract][Full Text] [Related]  

  • 14. PhRMA CPCDC initiative on predictive models of human pharmacokinetics, part 4: prediction of plasma concentration-time profiles in human from in vivo preclinical data by using the Wajima approach.
    Vuppugalla R; Marathe P; He H; Jones RD; Yates JW; Jones HM; Gibson CR; Chien JY; Ring BJ; Adkison KK; Ku MS; Fischer V; Dutta S; Sinha VK; Björnsson T; Lavé T; Poulin P
    J Pharm Sci; 2011 Oct; 100(10):4111-26. PubMed ID: 21480234
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Preclinical assessment of the absorption and disposition of the phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor GDC-0980 and prediction of its pharmacokinetics and efficacy in human.
    Salphati L; Pang J; Plise EG; Lee LB; Olivero AG; Prior WW; Sampath D; Wong S; Zhang X
    Drug Metab Dispos; 2012 Sep; 40(9):1785-96. PubMed ID: 22696419
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Application of hybrid approach based on empirical and physiological concept for predicting pharmacokinetics in humans--usefulness of exponent on prospective evaluation of predictability.
    Sayama H; Komura H; Kogayu M
    Drug Metab Dispos; 2013 Feb; 41(2):498-507. PubMed ID: 23209193
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetic characterization of a natural product-inspired novel MEK1 inhibitor E6201 in preclinical species.
    Kumar V; Schuck EL; Pelletier RD; Farah N; Condon KB; Ye M; Rowbottom C; King BM; Zhang ZY; Saxton PL; Wong YN
    Cancer Chemother Pharmacol; 2012 Jan; 69(1):229-37. PubMed ID: 21698359
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Biotransformation of a novel antimitotic agent, I-387, by mouse, rat, dog, monkey, and human liver microsomes and in vivo pharmacokinetics in mice.
    Ahn S; Kearbey JD; Li CM; Duke CB; Miller DD; Dalton JT
    Drug Metab Dispos; 2011 Apr; 39(4):636-43. PubMed ID: 21233217
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Animal pharmacokinetics and interspecies scaling from animals to man of lamifiban, a new platelet aggregation inhibitor.
    Lave T; Saner A; Coassolo P; Brandt R; Schmitt-Hoffmann AH; Chou RC
    J Pharm Pharmacol; 1996 Jun; 48(6):573-7. PubMed ID: 8832489
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Human pharmacokinetic prediction of UDP-glucuronosyltransferase substrates with an animal scale-up approach.
    Deguchi T; Watanabe N; Kurihara A; Igeta K; Ikenaga H; Fusegawa K; Suzuki N; Murata S; Hirouchi M; Furuta Y; Iwasaki M; Okazaki O; Izumi T
    Drug Metab Dispos; 2011 May; 39(5):820-9. PubMed ID: 21282406
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.